HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Aquestive Therapeutics (NASDAQ:AQST) and maintained a $5 price target.
September 22, 2023 | 10:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aquestive Therapeutics (NASDAQ:AQST) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $5.
The 'Buy' rating from HC Wainwright & Co. indicates a positive outlook for Aquestive Therapeutics. The maintained price target of $5 suggests that the analyst believes the stock is undervalued at current levels. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100